Condition
Hermansky-Pudlak Syndrome (HPS)
Total Trials
4
Recruiting
1
Active
2
Completed
1
Success Rate
50.0%-37% vs avg
Key Insights
Highlights
Success Rate
50% trial completion
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 75/100
Termination Rate
25.0%
1 terminated out of 4 trials
Success Rate
50.0%
-36.5% vs benchmark
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
100%
1 of 1 completed with results
Key Signals
1 with results50% success
Data Visualizations
Phase Distribution
1Total
P 1 (1)
Trial Status
Completed1
Active Not Recruiting1
Terminated1
Recruiting1
Trial Success Rate
50.0%
Benchmark: 86.5%
Based on 1 completed trials
Clinical Trials (4)
Showing 4 of 4 trials
NCT00084305Active Not Recruiting
Analysis of Specimens From Individuals With Pulmonary Fibrosis
NCT00001456RecruitingPrimary
Clinical and Basic Investigations Into Hermansky-Pudlak Syndrome
NCT01417520Completed
Clinical and Pathophysiological Investigations Into Erdheim Chester Disease
NCT00467831Phase 1TerminatedPrimary
Pilot Study of a Multi-Drug Regimen for Severe Pulmonary Fibrosis in Hermansky-Pudlak Syndrome
Showing all 4 trials